Featured Clinical Trials Supported by the National Cancer Institute
Today, thousands of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials and demonstrates the breadth of clinical cancer research supported by the Institute.
To find other cancer trials open to enrollment:
- Call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
- Use the clinical trials search form to look online for trials listed on NCI's Cancer.gov website. The form has a Help link for tips about searching for clinical trials.
- For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call NCI’s Clinical Trials Referral Office at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
(Posted: 07/28/2009) - In this trial, patients with advanced non-small cell lung cancer that has recurred or progressed after initial chemotherapy will be tested for EGFR gene amplification and then randomly assigned to receive either pemetrexed or erlotinib.
Combining Immunotoxin and Chemotherapy for Pleural Mesothelioma
(Posted: 07/14/2009) - In this trial, patients with inoperable epithelial pleural mesothelioma will be given SS1P immunotoxin in combination with pemetrexed and cisplatin to determine the maximum tolerated dose of SS1P and side effects profile in these patients.
Testing Trabectedin in Pediatric Patients
(Posted: 06/30/2009) - In this phase I clinical trial, children with solid tumors that have either recurred or have not responded to previous treatment will be treated with trabectedin.
Optimizing Postoperative Chemotherapy for Breast Cancer
(Posted: 06/16/2009) - In this trial, women with early-stage breast cancer deemed by their doctors to be at high risk for recurrence will receive adjuvant chemotherapy with either cyclophosphamide and doxorubicin or paclitaxel given four times over an 8-week period.
Cetuximab and Chemoradiotherapy for Locally Advanced Esophageal Cancer
(Posted: 05/19/2009) - In this trial, patients with locally advanced esophageal cancer will undergo chemoradiotherapy using the drugs cisplatin and paclitaxel, and half of them will be randomly assigned to also receive the biologic agent cetuximab.